vs
Ecovyst Inc.（ECVT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Ecovyst Inc.的1.1倍（$219.9M vs $199.4M），Ecovyst Inc.同比增速更快（34.0% vs 2.0%），Ecovyst Inc.自由现金流更多（$22.9M vs $16.8M），过去两年Ecovyst Inc.的营收复合增速更高（18.7% vs 8.0%）
Ecovyst Inc.是一家全球可持续特种材料供应商，主营高性能催化剂与功能性添加剂的研发、生产，产品服务覆盖工业制造、消费品、环保等核心领域，助力全球客户提升运营效率、降低碳排放。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ECVT vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$199.4M
营收增速更快
ECVT
高出32.0%
2.0%
自由现金流更多
ECVT
多$6.1M
$16.8M
两年增速更快
ECVT
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.4M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 23.4% | 71.1% |
| 营业利润率 | 10.9% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 34.0% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ECVTOFIX
| Q4 25 | $199.4M | $219.9M | ||
| Q3 25 | $204.9M | $205.6M | ||
| Q2 25 | $176.1M | $203.1M | ||
| Q1 25 | $143.1M | $193.6M | ||
| Q4 24 | $148.9M | $215.7M | ||
| Q3 24 | $153.9M | $196.6M | ||
| Q2 24 | $154.0M | $198.6M | ||
| Q1 24 | $141.6M | $188.6M |
净利润ECVTOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-79.3M | $-22.8M | ||
| Q2 25 | $6.0M | $-14.1M | ||
| Q1 25 | $-3.6M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $14.3M | $-27.4M | ||
| Q2 24 | $8.3M | $-33.4M | ||
| Q1 24 | $1.2M | $-36.0M |
毛利率ECVTOFIX
| Q4 25 | 23.4% | 71.1% | ||
| Q3 25 | 25.4% | 72.2% | ||
| Q2 25 | 22.8% | 68.7% | ||
| Q1 25 | 13.3% | 62.8% | ||
| Q4 24 | 28.9% | 69.0% | ||
| Q3 24 | 29.3% | 68.7% | ||
| Q2 24 | 27.3% | 67.8% | ||
| Q1 24 | 23.5% | 67.5% |
营业利润率ECVTOFIX
| Q4 25 | 10.9% | 0.2% | ||
| Q3 25 | 13.8% | -8.3% | ||
| Q2 25 | 9.0% | -7.9% | ||
| Q1 25 | -0.7% | -25.2% | ||
| Q4 24 | 15.1% | -5.3% | ||
| Q3 24 | 17.9% | -9.6% | ||
| Q2 24 | 14.1% | -12.5% | ||
| Q1 24 | 9.5% | -15.6% |
净利率ECVTOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -38.7% | -11.1% | ||
| Q2 25 | 3.4% | -6.9% | ||
| Q1 25 | -2.5% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 9.3% | -13.9% | ||
| Q2 24 | 5.4% | -16.8% | ||
| Q1 24 | 0.9% | -19.1% |
每股收益（稀释后）ECVTOFIX
| Q4 25 | $0.06 | $-0.05 | ||
| Q3 25 | $-0.69 | $-0.57 | ||
| Q2 25 | $0.05 | $-0.36 | ||
| Q1 25 | $-0.03 | $-1.35 | ||
| Q4 24 | $-0.26 | $-0.76 | ||
| Q3 24 | $0.12 | $-0.71 | ||
| Q2 24 | $0.07 | $-0.88 | ||
| Q1 24 | $0.01 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.2M | $82.0M |
| 总债务越低越好 | $392.6M | — |
| 股东权益账面价值 | $603.4M | $450.0M |
| 总资产 | $1.3B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.65× | — |
8季度趋势，按日历期对齐
现金及短期投资ECVTOFIX
| Q4 25 | $197.2M | $82.0M | ||
| Q3 25 | $82.0M | $62.9M | ||
| Q2 25 | $69.6M | $65.6M | ||
| Q1 25 | $127.5M | $58.0M | ||
| Q4 24 | $131.4M | $83.2M | ||
| Q3 24 | $123.5M | $30.1M | ||
| Q2 24 | $83.3M | $26.4M | ||
| Q1 24 | $103.1M | $27.0M |
总债务ECVTOFIX
| Q4 25 | $392.6M | — | ||
| Q3 25 | $854.8M | $157.2M | ||
| Q2 25 | $856.6M | $157.0M | ||
| Q1 25 | $859.0M | $156.9M | ||
| Q4 24 | $860.8M | $157.0M | ||
| Q3 24 | $862.7M | $118.5M | ||
| Q2 24 | $862.4M | $118.0M | ||
| Q1 24 | $866.2M | $118.2M |
股东权益ECVTOFIX
| Q4 25 | $603.4M | $450.0M | ||
| Q3 25 | $607.9M | $442.5M | ||
| Q2 25 | $692.4M | $458.3M | ||
| Q1 25 | $698.7M | $458.3M | ||
| Q4 24 | $700.5M | $503.1M | ||
| Q3 24 | $729.4M | $525.9M | ||
| Q2 24 | $717.3M | $546.0M | ||
| Q1 24 | $711.4M | $570.3M |
总资产ECVTOFIX
| Q4 25 | $1.3B | $850.6M | ||
| Q3 25 | $1.7B | $832.6M | ||
| Q2 25 | $1.8B | $837.2M | ||
| Q1 25 | $1.8B | $823.1M | ||
| Q4 24 | $1.8B | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $1.8B | $882.0M | ||
| Q1 24 | $1.8B | $906.0M |
负债/权益比ECVTOFIX
| Q4 25 | 0.65× | — | ||
| Q3 25 | 1.41× | 0.36× | ||
| Q2 25 | 1.24× | 0.34× | ||
| Q1 25 | 1.23× | 0.34× | ||
| Q4 24 | 1.23× | 0.31× | ||
| Q3 24 | 1.18× | 0.23× | ||
| Q2 24 | 1.20× | 0.22× | ||
| Q1 24 | 1.22× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $41.8M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $22.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 11.5% | 7.6% |
| 资本支出强度资本支出/营收 | 9.4% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $69.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ECVTOFIX
| Q4 25 | $41.8M | $27.7M | ||
| Q3 25 | $55.3M | $12.4M | ||
| Q2 25 | $33.0M | $11.6M | ||
| Q1 25 | $10.3M | $-18.4M | ||
| Q4 24 | $43.5M | $23.7M | ||
| Q3 24 | $59.9M | $11.7M | ||
| Q2 24 | $10.0M | $9.0M | ||
| Q1 24 | $36.5M | $-18.6M |
自由现金流ECVTOFIX
| Q4 25 | $22.9M | $16.8M | ||
| Q3 25 | $53.2M | $2.5M | ||
| Q2 25 | $7.8M | $4.5M | ||
| Q1 25 | $-14.0M | $-25.1M | ||
| Q4 24 | $30.9M | $15.2M | ||
| Q3 24 | $53.6M | $6.3M | ||
| Q2 24 | $-9.3M | $-360.0K | ||
| Q1 24 | $19.1M | $-29.1M |
自由现金流率ECVTOFIX
| Q4 25 | 11.5% | 7.6% | ||
| Q3 25 | 26.0% | 1.2% | ||
| Q2 25 | 4.4% | 2.2% | ||
| Q1 25 | -9.8% | -13.0% | ||
| Q4 24 | 20.7% | 7.0% | ||
| Q3 24 | 34.9% | 3.2% | ||
| Q2 24 | -6.1% | -0.2% | ||
| Q1 24 | 13.5% | -15.4% |
资本支出强度ECVTOFIX
| Q4 25 | 9.4% | 4.9% | ||
| Q3 25 | 1.0% | 4.8% | ||
| Q2 25 | 14.4% | 3.5% | ||
| Q1 25 | 16.9% | 3.5% | ||
| Q4 24 | 8.5% | 4.0% | ||
| Q3 24 | 4.1% | 2.7% | ||
| Q2 24 | 12.5% | 4.7% | ||
| Q1 24 | 12.3% | 5.6% |
现金转化率ECVTOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 5.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.21× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 29.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
